5-(甲氧羰基)双环[3.2.2]壬烷-1-羧酸 | 942999-81-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 5-(甲氧羰基)双环[3.2.2]壬烷-1-羧酸
• 英文名称: methoxycarbonylbicyclo[3.2.2]nonane-5-carboxylic acid
• 英文别名: bicyclo[3.2.2]nonane-1,5-dicarboxylic acid monomethyl ester；5-(Methoxycarbonyl)bicyclo[3.2.2]nonane-1-carboxylic acid；5-methoxycarbonylbicyclo[3.2.2]nonane-1-carboxylic acid
• CAS: 942999-81-7
• 化学式: C₁₂H₁₈O₄
• 分子量: 226.273
• InChiKey: ZUZBTCVOLMTOBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(甲氧羰基)双环[3.2.2]壬烷-1-羧酸 在 sodium hydroxide 、 silver nitrate 、 溴 作用下， 以 水 、 丙酮 、 Petroleum ether 为溶剂， 反应 2.34h， 以37%的产率得到methyl 5-bromobicyclo[3.2.2]nonane-1-carboxylate
  参考文献：
  名称：

  Discovery of a Potent, Selective, and Orally Efficacious Pyrimidinooxazinyl Bicyclooctaneacetic Acid Diacylglycerol Acyltransferase-1 Inhibitor

  摘要：

  Inhibition of DGAT-1 is increasingly seen as an attractive mechanism with the potential for treatment of obesity and other elements of the metabolic syndrome. We report here a bicyclooctaneacetic acid derivative in the pyrimidinooxazine structural class of DGAT-1 inhibitors that has good potency, selectivity, and pharmacokinetic characteristics across a variety of species. This compound is an effective inhibitor of DGAT-1 in both intestinal and adipose tissue, which results in a reduction in body weight or body weight gain following oral administration in both mouse and rat models of dietary-induced obesity.

  DOI：

  10.1021/jm801507v
• 作为产物：
  描述：

  1,5-二甲基双环[3.2.2]壬烷-1,5-二羧酸酯 在 甲醇 、 barium dihydroxide 、 水 、 盐酸 作用下， 以49%的产率得到5-(甲氧羰基)双环[3.2.2]壬烷-1-羧酸
  参考文献：
  名称：

  WO2007/71966

  摘要：

  公开号：

文献信息

• Pyrimido [4,5-B] -Oxazines For Use as Dgat Inhibitors
  申请人：Birch Alan Martin

  公开号：US20080306059A1

  公开（公告）日：2008-12-11

  Compounds of formula (I) or salts thereof, wherein A, and R 1 to R 5 are as defined in the specification, are DGAT-1 inhibitors and are thereby useful in the treatment of, for example, obesity. Processes to make compounds of formula (I) are also described.

  化合物公式（I）或其盐，其中A和R1至R5如规范中所定义，是DGAT-1抑制剂，因此在治疗肥胖等方面非常有用。本文还描述了制备化合物公式（I）的过程。
• Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
  申请人：AstraZeneca AB

  公开号：US07749997B2

  公开（公告）日：2010-07-06

  Compounds of formula (I) or salts thereof, wherein A, and R1 to R5 are as defined in the specification, are DGAT-1 inhibitors and are thereby useful in the treatment of, for example, obesity. Processes to make compounds of formula (I) are also described.

  式(I)的化合物或其盐，其中A和R1至R5如规范所定义，是DGAT-1抑制剂，因此在治疗肥胖症等方面有用。还描述了制备式(I)化合物的过程。
• Pyrimido [4,5-B]-oxazines for use as DGAT inhibitors
  申请人：AstraZeneca AB

  公开号：US08017603B2

  公开（公告）日：2011-09-13

  Compounds of formula (I) or salts thereof, wherein A, and R1 to R5 are as defined in the specification, are DGAT-1 inhibitors and are thereby useful in the treatment of, for example, obesity. Processes to make compounds of formula (I) are also described.

  公式（I）的化合物或其盐，其中A和R1至R5如规范所定义，是DGAT-1抑制剂，因此在治疗肥胖等方面是有用的。本文还描述了制备公式（I）化合物的过程。
• PYRIMIDO [4,5-B] -OXAZINES FOR USE AS DGAT INHIBITORS
  申请人：Birch Alan Martin

  公开号：US20100311737A1

  公开（公告）日：2010-12-09

  Compounds of formula (I) or salts thereof, wherein A, and R 1 to R 5 are as defined in the specification, are DGAT-1 inhibitors and are thereby useful in the treatment of, for example, obesity. Processes to make compounds of formula (I) are also described.

  式(I)化合物或其盐，其中A和R1到R5如规范中所定义，是DGAT-1抑制剂，因此在治疗肥胖症等方面有用。本文还描述了制备式(I)化合物的过程。
• WO2007/71966
  申请人：——

  公开号：——

  公开（公告）日：——